TABLE 1.
Agents affecting signaling pathways studied in vitro
| Agent | Mode of action | Signaling | In vitro doses (µM) |
|---|---|---|---|
| Doxazosin (Dox) | α1-AR antagonist | Gq | 10, 100, 1000 |
| Phenoxybenzamine (PBA) | α-AR antagonist | Gq | 10, 20 |
| Prazosin (PRA) | α1-AR antagonist | Gq | 0.5, 5 |
| U73122 | PLC inhibitor | — | 1, 5, 10 |
| 2-APB | IP3 receptor inhibitor | — | 10, 100, 200 |
| Ruthenium red (RR) | Calcium release from ER inhibitor | — | 5, 10 |
| Apocynin (Apo) | NADPH oxidase inhibitor | — | 10, 100, 1000 |
| Lofexidine (Lof) | α2-AR agonist | Gi | 10, 100, 1000 |
| Guanabenz (Gub) | α2-AR agonist | Gi | 1, 10 |
| Brimonidine (Brim) | α2-AR agonist | Gi | 1, 10 |
| LY 215840 (LY) | 5-HT2R/5-HT7R antagonist | Gs, Gq | 10, 100 |
| RO 04-6790 (RO) | 5-HT6 R antagonist | Gs | 10, 100 |
| RS 23597-190 (RS) | 5-HT4R antagonist | Gs | 10, 100 |
| Dibutyryl cAMP (db cAMP) | Adenylate cyclase agonist | Gs | 200, 500, 1000 |
| sp-5,6-DCI-cBIMPS | cAMP analog, PKA activator | Gs | 1, 10, 50 |
| SQ 22536 (SQ) | Adenylate cyclase antagonist | Gs | 50, 500 |
| IBMX | Phosphodiesterase inhibitor | Gs | 30, 100, 225 |
| KT5720 | PKA inhibitor | Gs | 0.05, 2 |
| Forskolin | Adenylate cyclase agonist | Gs | 10 |
Assays performed in vitro with 661W cells are described in the Materials and Methods section.